BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
BNB$577.36-1.84%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
BNB$577.36-1.84%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
Eli Lilly shares surged over 4.5% on analyst upgrades, acquisition rumors involving Ventyx Biosciences, and a new $1.3 billion research partnership.
The assassination of UnitedHealthcare CEO Brian Thompson has sparked a national debate on healthcare reform in the United States.
Eli Lilly and Novo Nordisk continue to capitalize on unprecedented interest for weight-loss drugs, with both companies posting strong Q3 results on Thursday.
Several drugmakers have been thriving on the ongoing weight-loss trend, with Denmark's Novo Nordisk and Eli Lilly standing out in particular.
Shares of drugmaker Ars Pharmaceuticals crashed over 57% after FDA disapproved its EpiPen alternative.
Got an extra $500? Take a look at these long-term, much-anticipated stocks.